Dr. Reddy’s Laboratories on Saturday held that it had signed a pact with New Jersey-based Slayback Pharma to acquire rights to a medication that relieves redness of the eyes. Under the licensing pact, the company has acquired rights in Brimonidine Tartrate Ophthalmic Solution 0.025 per cent.

Brimonidine is an alpha-2 adrenergic receptor agonist which relieves eyes’ redness and results in no dilated pupils (mydriasis). Topical administration of brimonidine tartrate reduces intraocular pressure in humans with negligible effect on cardiovascular or pulmonary parameters.

• L&T Shares Trade With Nominal Losses Despite Securing Orders 
• Daily vs Weekly SIP: Which Can Supercharge Your Portfolio to the Million-Mark?
• Rail Vikas Nigam Shares Take a Hit Despite Rs 165 Crore Order 
• Lupin Shares Gain 1% as Unit Receives EIR Status from USFDA
• Glenmark Unit Signs Exclusive NSCLC Drug Pact with Hansoh Pharma; Shares Drop 1%

The company’s product, in composition, is equivalent to Lumify. This over-the-counter (OTC) eye drop is primarily used to reduce the eyes’ redness due to minor irritations. The official agreement also provides Dr. Reddy’s exclusive rights to the product outside the USA.

According to industry estimates, the total addressable market value for this product in the US is around USD 130 million for one year ending June 2022. As India is home to one of the largest cases of ophthalmic disorders, Dr. Reddy’s Laboratories sees this as an opportunity to address a large market.